SCHEMBL7531771

SCHEMBL7531771

[CH2]CN(C(=O)c1ccccc1)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TRPM8 Q7Z2W7 2/20 0.44
ALDH1A1 P00352 3/20 0.43
HTR2A P28223 2/20 0.43
HPGD P15428 2/20 0.43
PGR P06401 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
HRH1 P35367 1/20 0.43
KCNH2 Q12809 1/20 0.43
HSD11B1 P28845 1/20 0.43
LMNA P02545 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPSR1 Q6W5P4 2/20 0.43
MAPT P10636 2/20 0.43
MLYCD O95822 1/20 0.43
XBP1 P17861 1/20 0.43
ATM Q13315 1/20 0.43
HTR1A P08908 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1004615 0.83 NAMPT (0.55) MEN1KMT2ATRPM8ALDH1A1HTR2A
SCHEMBL7528191 0.81 HPGD (0.48) MEN1KMT2AALDH1A1HPGDSMN1; SMN2
SCHEMBL29173030 0.81 EGFR (0.47) MEN1KMT2ATRPM8ALDH1A1HTR2A
SCHEMBL1003822 0.80 HTR1A (0.47) MEN1KMT2ATRPM8ALDH1A1HTR2A
SCHEMBL2592951 0.80 CES2 (0.47) HPGDLMNAMAPTTP53TSHR
SCHEMBL23791942 0.79 HTR1A (0.46) MEN1KMT2ATRPM8ALDH1A1HTR2A
SCHEMBL1003732 0.79 ADRA2C (0.49) MEN1KMT2ATRPM8ALDH1A1HTR2A
SCHEMBL12130667 0.77 MEN1 (0.54) MEN1KMT2AHTR2AHPGDMLYCD
SCHEMBL14427596 0.76 MEN1 (0.67) MEN1KMT2AHSD11B1LMNANPSR1
SCHEMBL8034861 0.76 HTR1A (0.50) MEN1KMT2ATRPM8HTR2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020147331-A1 Methods for synthesis of oligonucleotides ISIS PHARMACEUTICALS, INC. 2002-10-10 US claimed
WO-2002062811-A2 IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2002-08-15 WO claimed
US-20020147331-A1 Methods for synthesis of oligonucleotides ISIS PHARMACEUTICALS, INC. 2002-10-10 US disclosed
WO-2002062811-A2 IMPROVED METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES ISIS PHARMACEUTICALS, INC. (US) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147331-A1 Methods for synthesis of oligonucleotides RNGTT, TYMP, PNP MEN1 2222/4885KMT2A 3974/4885TRPM8 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.